No association of breast cancer risk with integrin beta3 (ITGB3) Leu33Pro genotype

S E Bojesen; A Tybjaerg-Hansen; C K Axelsson; B G Nordestgaard

doi:10.1038/sj.bjc.6602674

No association of breast cancer risk with integrin beta3 (ITGB3) Leu33Pro genotype

S E Bojesen, A Tybjaerg-Hansen, C K Axelsson, B G Nordestgaard

9 Citations (Scopus)

Abstract

To pursue a borderline increased risk of breast cancer for carriers of two integrin beta(3) (ITGB3) 33Pro alleles found in a recent prospective study, we conducted a case-control study of 1088 women with breast cancer and 4815 female controls. Leu33Pro heterozygotes, homozygotes and heterozygotes+homozygotes vs noncarriers had odds ratios for breast cancer of 1.0 (95% confidence interval: 0.8-1.1), 0.8 (0.5-1.2) and 1.0 (0.8-1.1), respectively. After stratification for conventional risk factors, odds ratio for breast cancer in heterozygotes, homozygotes and heterozygotes+homozygotes vs noncarriers were not increased above 1.0 in any of the 14 strata examined. This was also true after stratification for tumour histological subtype and cancer stage at the time of diagnosis.

Original language	English
Journal	British Journal of Cancer
Volume	93
Issue number	1
Pages (from-to)	167-71
Number of pages	5
ISSN	0007-0920
DOIs	https://doi.org/10.1038/sj.bjc.6602674
Publication status	Published - 11 Jul 2005
Externally published	Yes

Keywords

Adult
Aged
Aged, 80 and over
Breast Neoplasms/genetics
Case-Control Studies
Female
Genetic Predisposition to Disease
Genotype
Humans
Integrin beta3/chemistry
Leucine/genetics
Middle Aged
Proline/genetics

Access to Document

10.1038/sj.bjc.6602674

Cite this

@article{8f5034f6fc3045659dba6e11b1ec029f,

title = "No association of breast cancer risk with integrin beta3 (ITGB3) Leu33Pro genotype",

abstract = "To pursue a borderline increased risk of breast cancer for carriers of two integrin beta(3) (ITGB3) 33Pro alleles found in a recent prospective study, we conducted a case-control study of 1088 women with breast cancer and 4815 female controls. Leu33Pro heterozygotes, homozygotes and heterozygotes+homozygotes vs noncarriers had odds ratios for breast cancer of 1.0 (95\% confidence interval: 0.8-1.1), 0.8 (0.5-1.2) and 1.0 (0.8-1.1), respectively. After stratification for conventional risk factors, odds ratio for breast cancer in heterozygotes, homozygotes and heterozygotes+homozygotes vs noncarriers were not increased above 1.0 in any of the 14 strata examined. This was also true after stratification for tumour histological subtype and cancer stage at the time of diagnosis.",

keywords = "Adult, Aged, Aged, 80 and over, Breast Neoplasms/genetics, Case-Control Studies, Female, Genetic Predisposition to Disease, Genotype, Humans, Integrin beta3/chemistry, Leucine/genetics, Middle Aged, Proline/genetics",

author = "Bojesen, \{S E\} and A Tybjaerg-Hansen and Axelsson, \{C K\} and Nordestgaard, \{B G\}",

year = "2005",

month = jul,

day = "11",

doi = "10.1038/sj.bjc.6602674",

language = "English",

volume = "93",

pages = "167--71",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - No association of breast cancer risk with integrin beta3 (ITGB3) Leu33Pro genotype

AU - Bojesen, S E

AU - Tybjaerg-Hansen, A

AU - Axelsson, C K

AU - Nordestgaard, B G

PY - 2005/7/11

Y1 - 2005/7/11

N2 - To pursue a borderline increased risk of breast cancer for carriers of two integrin beta(3) (ITGB3) 33Pro alleles found in a recent prospective study, we conducted a case-control study of 1088 women with breast cancer and 4815 female controls. Leu33Pro heterozygotes, homozygotes and heterozygotes+homozygotes vs noncarriers had odds ratios for breast cancer of 1.0 (95% confidence interval: 0.8-1.1), 0.8 (0.5-1.2) and 1.0 (0.8-1.1), respectively. After stratification for conventional risk factors, odds ratio for breast cancer in heterozygotes, homozygotes and heterozygotes+homozygotes vs noncarriers were not increased above 1.0 in any of the 14 strata examined. This was also true after stratification for tumour histological subtype and cancer stage at the time of diagnosis.

AB - To pursue a borderline increased risk of breast cancer for carriers of two integrin beta(3) (ITGB3) 33Pro alleles found in a recent prospective study, we conducted a case-control study of 1088 women with breast cancer and 4815 female controls. Leu33Pro heterozygotes, homozygotes and heterozygotes+homozygotes vs noncarriers had odds ratios for breast cancer of 1.0 (95% confidence interval: 0.8-1.1), 0.8 (0.5-1.2) and 1.0 (0.8-1.1), respectively. After stratification for conventional risk factors, odds ratio for breast cancer in heterozygotes, homozygotes and heterozygotes+homozygotes vs noncarriers were not increased above 1.0 in any of the 14 strata examined. This was also true after stratification for tumour histological subtype and cancer stage at the time of diagnosis.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Breast Neoplasms/genetics

KW - Case-Control Studies

KW - Female

KW - Genetic Predisposition to Disease

KW - Genotype

KW - Humans

KW - Integrin beta3/chemistry

KW - Leucine/genetics

KW - Middle Aged

KW - Proline/genetics

UR - https://www.scopus.com/pages/publications/23044481934

U2 - 10.1038/sj.bjc.6602674

DO - 10.1038/sj.bjc.6602674

M3 - Journal article

C2 - 15970922

SN - 0007-0920

VL - 93

SP - 167

EP - 171

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 1

ER -

No association of breast cancer risk with integrin beta3 (ITGB3) Leu33Pro genotype

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this